Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
Age
Any age
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Patients with CRPC progressing during the course of first line docetaxel-based chemotherapy or after at least 3 cycles (equivalent to 225mg/m2) of first line docetaxel-based chemotherapy
Patient who have given their written consent
You may not be if
Current participation in a clinical trial for the second-line treatment of prostate cancer
Patients having received less than 3 cycles of first line docetaxel-based chemotherapy and discontinued for a reason other than disease progression or toxicity
Patients having already started a second line treatment
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
